Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Talis Biomedical Corp (TLIS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Investor presentation, Quarterly results
Docs: "Talis Biomedical Corporation Condensed Balance Sheets June 30, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 98,200 $ 130,191 Restricted cash 1,010 — Accounts receivable, net 532 308 Prepaid expenses and other current assets 2,223 2,783 Total current assets 101,965 133,282 Property and equipment, net 3,539 3,312 Operating lease right-of-use-assets 16,030 30,920 Other long-term assets 1,542 1,776 Total assets $ 123,076 $ 169,290 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 2,491 $ 3,768 Accrued compensation 3,097 4,212 Accrued liabilities 938 989 Operating lease liabilities, current portion 2,736 3,703 Total current liabilities 9,262 12,672 Operating lease liabilities, long-term portion 17,648 29,879 Total liabilities $ 26,910 $ 42...",
"COVID ACCELERATED POC PLATFORM ADOPTION"
08/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/02/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
08/02/2023 8-K Quarterly results
07/27/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "New Data Presented at the Infectious Disease Society for Obstetrics and Gynecology Annual Meeting Differentiate Talis Biomedical’s Women’s and Sexual Health Product Menu Preliminary data suggest a chlamydia, gonorrhea and trichomonas multiplex test is feasible on a molecular point-of-care test system with time to result in less than 30 minutes Ability to effectively lyse challenging fungal pathogens, including Candida, in under four minutes on Talis One® system positions Company to develop POC vaginal infection panel"
07/24/2023 8-K Quarterly results
07/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/05/2023 8-K Quarterly results
06/12/2023 4 Scott Randal W. (Director) has filed a Form 4 on Talis Biomedical Corp
Txns: Granted 95,000 options to buy @ $0.5, valued at $47.5k
06/12/2023 4 Posard Matthew L. (Director) has filed a Form 4 on Talis Biomedical Corp
Txns: Granted 95,000 options to buy @ $0.5, valued at $47.5k
06/12/2023 4 Popovits Kimberly J (Director) has filed a Form 4 on Talis Biomedical Corp
Txns: Granted 95,000 options to buy @ $0.5, valued at $47.5k
06/12/2023 4 Gilliam Melissa (Director) has filed a Form 4 on Talis Biomedical Corp
Txns: Granted 95,000 options to buy @ $0.5, valued at $47.5k
06/12/2023 4 Ismagilov Rustem F. (Director) has filed a Form 4 on Talis Biomedical Corp
Txns: Granted 95,000 options to buy @ $0.5, valued at $47.5k
06/12/2023 4 Dreismann Heinrich (Director) has filed a Form 4 on Talis Biomedical Corp
Txns: Granted 5,466 options to buy @ $0.5, valued at $2.7k
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/23/2023 4 Dreismann Heinrich (Director) has filed a Form 4 on Talis Biomedical Corp
Txns: Granted 190,000 options to buy @ $0.46, valued at $87.4k
05/23/2023 3 Dreismann Heinrich (Director) has filed a Form 3 on Talis Biomedical Corp
05/23/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Investor presentation, Quarterly results
Docs: "Talis Biomedical Corporation Condensed Balance Sheets March 31 December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 112,959 $ 130,191 Restricted cash 1,010 — Accounts receivable, net 127 308 Prepaid expenses and other current assets 1,492 2,783 Total current assets 115,588 133,282 Property and equipment, net 3,634 3,312 Operating lease right-of-use-assets 12,289 30,920 Other long-term assets 1,542 1,776 Total assets $ 133,053 $ 169,290 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 3,871 $ 3,768 Accrued compensation 2,733 4,212 Accrued liabilities 1,614 989 Operating lease liabilities, current portion 2,962 3,703 Total current liabilities 11,180 12,672 Operating lease liabilities, long-term portion 11,749 29,879 Total liabilities $ 22,929 ...",
"COVID ACCELERATED POC PLATFORM ADOPTION"
05/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
04/25/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
04/18/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/22/2023 10-K Annual Report for the period ended December 31, 2022
03/10/2023 SC 13D/A BAKER BROS. ADVISORS LP reports a 66.2% stake in Talis Biomedical Corporation
03/10/2023 3 Cheong Raymond (Director) has filed a Form 3 on Talis Biomedical Corp
03/10/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/14/2023 SC 13G/A Greenlight Capital reports a 8.3% stake in Talis Biomedical Corporation
01/25/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
09/12/2022 SC 13G/A ArrowMark Colorado Holdings LLC reports a 4.8% stake in Talis Biomedical Corporation
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy